Replies to post #145401 on Biotech Values

[mcbio]

There must be a lot of suckers who thought that changing the SAP in midstream was bullish.

I would assume that one modifies their SAP midstream because they're not, or don't expect to be, satisfied with the results. I guess with the trial being double-blinded, presumably it could be the latter. And, regardless, doesn't the changing of the SAP midstream impact the p values and other measures compared to if the SAP had not been modified?

Perhaps investors are bullish because results will be reported four months earlier but just because they will be reported earlier in no way increases the chances of success.

[DonShimoda]

There must be a lot of suckers who thought that changing the SAP in midstream was bullish.

I say welcome aboard and here's a bucket. Now, please start bailing me out of my position, lol.

fwiw, the company's epilepsy drug, CPP115, has potential but until they find a partner the value will remain unrealized. Until then the stock will be driven by CPP109, which is a coin flip. And now that the SAP has changed, the results will "be open to interpretation"....ugh. In hindsight, I should have initiated my position after the CPP109 results but before any partnership.

[DewDiligence]

CPRX off ~20% on warrant-laden financing:

http://finance.yahoo.com/news/catalyst-pharmaceutical-partners-inc-raises-120300197.html